Cargando…

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study

BACKGROUND: Denosumab treatment for up to 8 years in the FREEDOM study and Extension was associated with low fracture incidence. It was not clear whether subjects who discontinued during the study conduct had a higher risk of fracture than those who remained enrolled, thereby underestimating the tru...

Descripción completa

Detalles Bibliográficos
Autores principales: Adachi, Jonathan D., Bone, Henry G., Daizadeh, Nadia S., Dakin, Paula, Papapoulos, Socrates, Hadji, Peyman, Recknor, Chris, Bolognese, Michael A., Wang, Andrea, Lin, Celia J. F., Wagman, Rachel B., Ferrari, Serge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408481/
https://www.ncbi.nlm.nih.gov/pubmed/28449657
http://dx.doi.org/10.1186/s12891-017-1520-6
_version_ 1783232316077768704
author Adachi, Jonathan D.
Bone, Henry G.
Daizadeh, Nadia S.
Dakin, Paula
Papapoulos, Socrates
Hadji, Peyman
Recknor, Chris
Bolognese, Michael A.
Wang, Andrea
Lin, Celia J. F.
Wagman, Rachel B.
Ferrari, Serge
author_facet Adachi, Jonathan D.
Bone, Henry G.
Daizadeh, Nadia S.
Dakin, Paula
Papapoulos, Socrates
Hadji, Peyman
Recknor, Chris
Bolognese, Michael A.
Wang, Andrea
Lin, Celia J. F.
Wagman, Rachel B.
Ferrari, Serge
author_sort Adachi, Jonathan D.
collection PubMed
description BACKGROUND: Denosumab treatment for up to 8 years in the FREEDOM study and Extension was associated with low fracture incidence. It was not clear whether subjects who discontinued during the study conduct had a higher risk of fracture than those who remained enrolled, thereby underestimating the true fracture risk for the entire trial cohort. Thus, we explored the influence of early withdrawals on nonvertebral fracture incidence during the Extension study. METHODS: To understand the potential effect of depletion of susceptible subjects on fracture incidence, we first evaluated subject characteristics in patients who were enrolled in the Extension vs those who were not. We subsequently employed a Kaplan-Meier multiple imputation (KMMI) approach to consider subjects who discontinued as if they remained enrolled with a 0%, 20%, 50%, and 100% increase in fracture risk compared with participants remaining on study. RESULTS: Extension enrollees were generally similar to nonparticipants in median age (71.9 and 73.1 years, respectively), mean total hip bone mineral density T-score (–1.9 and –2.0, respectively), and probability of fracture risk by Fracture Risk Assessment Tool (FRAX(®)) at FREEDOM baseline (16.9% and 17.7% for major osteoporotic fracture and 6.7% and 7.4% for hip fracture, respectively). When we assumed a doubled fracture risk (100% increase) after discontinuation in KMMI analyses, nonvertebral fracture rate estimates were only marginally higher than the observed rates for both the crossover group (10.32% vs 9.16%, respectively) and the long-term group (7.63% vs 6.63%, respectively). CONCLUSION: The observation of continued denosumab efficacy over 8 years of treatment was robust and does not seem to be explained by depletion of susceptible subjects. TRIAL REGISTRATION: ClincalTrials.gov registration number NCT00523341; registered August 30, 2007 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12891-017-1520-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5408481
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54084812017-05-02 Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study Adachi, Jonathan D. Bone, Henry G. Daizadeh, Nadia S. Dakin, Paula Papapoulos, Socrates Hadji, Peyman Recknor, Chris Bolognese, Michael A. Wang, Andrea Lin, Celia J. F. Wagman, Rachel B. Ferrari, Serge BMC Musculoskelet Disord Research Article BACKGROUND: Denosumab treatment for up to 8 years in the FREEDOM study and Extension was associated with low fracture incidence. It was not clear whether subjects who discontinued during the study conduct had a higher risk of fracture than those who remained enrolled, thereby underestimating the true fracture risk for the entire trial cohort. Thus, we explored the influence of early withdrawals on nonvertebral fracture incidence during the Extension study. METHODS: To understand the potential effect of depletion of susceptible subjects on fracture incidence, we first evaluated subject characteristics in patients who were enrolled in the Extension vs those who were not. We subsequently employed a Kaplan-Meier multiple imputation (KMMI) approach to consider subjects who discontinued as if they remained enrolled with a 0%, 20%, 50%, and 100% increase in fracture risk compared with participants remaining on study. RESULTS: Extension enrollees were generally similar to nonparticipants in median age (71.9 and 73.1 years, respectively), mean total hip bone mineral density T-score (–1.9 and –2.0, respectively), and probability of fracture risk by Fracture Risk Assessment Tool (FRAX(®)) at FREEDOM baseline (16.9% and 17.7% for major osteoporotic fracture and 6.7% and 7.4% for hip fracture, respectively). When we assumed a doubled fracture risk (100% increase) after discontinuation in KMMI analyses, nonvertebral fracture rate estimates were only marginally higher than the observed rates for both the crossover group (10.32% vs 9.16%, respectively) and the long-term group (7.63% vs 6.63%, respectively). CONCLUSION: The observation of continued denosumab efficacy over 8 years of treatment was robust and does not seem to be explained by depletion of susceptible subjects. TRIAL REGISTRATION: ClincalTrials.gov registration number NCT00523341; registered August 30, 2007 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12891-017-1520-6) contains supplementary material, which is available to authorized users. BioMed Central 2017-04-27 /pmc/articles/PMC5408481/ /pubmed/28449657 http://dx.doi.org/10.1186/s12891-017-1520-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Adachi, Jonathan D.
Bone, Henry G.
Daizadeh, Nadia S.
Dakin, Paula
Papapoulos, Socrates
Hadji, Peyman
Recknor, Chris
Bolognese, Michael A.
Wang, Andrea
Lin, Celia J. F.
Wagman, Rachel B.
Ferrari, Serge
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
title Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
title_full Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
title_fullStr Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
title_full_unstemmed Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
title_short Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
title_sort influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab freedom extension study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408481/
https://www.ncbi.nlm.nih.gov/pubmed/28449657
http://dx.doi.org/10.1186/s12891-017-1520-6
work_keys_str_mv AT adachijonathand influenceofsubjectdiscontinuationonlongtermnonvertebralfracturerateinthedenosumabfreedomextensionstudy
AT bonehenryg influenceofsubjectdiscontinuationonlongtermnonvertebralfracturerateinthedenosumabfreedomextensionstudy
AT daizadehnadias influenceofsubjectdiscontinuationonlongtermnonvertebralfracturerateinthedenosumabfreedomextensionstudy
AT dakinpaula influenceofsubjectdiscontinuationonlongtermnonvertebralfracturerateinthedenosumabfreedomextensionstudy
AT papapoulossocrates influenceofsubjectdiscontinuationonlongtermnonvertebralfracturerateinthedenosumabfreedomextensionstudy
AT hadjipeyman influenceofsubjectdiscontinuationonlongtermnonvertebralfracturerateinthedenosumabfreedomextensionstudy
AT recknorchris influenceofsubjectdiscontinuationonlongtermnonvertebralfracturerateinthedenosumabfreedomextensionstudy
AT bolognesemichaela influenceofsubjectdiscontinuationonlongtermnonvertebralfracturerateinthedenosumabfreedomextensionstudy
AT wangandrea influenceofsubjectdiscontinuationonlongtermnonvertebralfracturerateinthedenosumabfreedomextensionstudy
AT linceliajf influenceofsubjectdiscontinuationonlongtermnonvertebralfracturerateinthedenosumabfreedomextensionstudy
AT wagmanrachelb influenceofsubjectdiscontinuationonlongtermnonvertebralfracturerateinthedenosumabfreedomextensionstudy
AT ferrariserge influenceofsubjectdiscontinuationonlongtermnonvertebralfracturerateinthedenosumabfreedomextensionstudy